Gongwin-KY announced on December 7 that its self-developed lung cancer drug, PTS-302 (ProSianAn), has officially been included in the first edition of China’s Commercial Health Insurance Innovative Drug Catalog. This qualification marks a significant entry into China’s rapidly growing commercial insurance market.

Market Implications:

• Sales Growth: Industry reports suggest that inclusion in this catalog typically leads to a 20–30% increase in peak sales, with high-value clinical drugs potentially seeing volumes double or triple in the short term.
• Clinical Value: In China, over 1.06 million new lung cancer cases were reported in 2022. Approx. 8–11% of these patients suffer from Malignant Airway Obstruction (MAO). PTS-302 is an innovative Minimally Invasive Targeted Tumor Ablation (MITTA) drug injected via bronchoscope.
• Accessibility: Currently used in over 253 Grade-A tertiary hospitals in China, the drug’s inclusion in the insurance catalog will significantly lower patient out-of-pocket costs and accelerate hospital adoption. Gongwin-KY expects sales to see exponential growth starting January 1, 2026, when the policy takes effect.

Resource: 共信成台股第一家獲納中國首版商保創新藥目錄 肺癌新藥銷售看增